Department of Internal Medicine, Huntsville Hospital, AL, USA.
Department of Infectious Disease, Huntsville Hospital, AL, USA.
J Infect Public Health. 2021 Nov;14(11):1668-1670. doi: 10.1016/j.jiph.2021.09.013. Epub 2021 Sep 23.
Coronavirus disease 2019 (COVID-19), which began in China, caused a global pandemic. Few studies have shown the benefit of hydroxychloroquine (HY) ± azithromycin (AZ) for treating COVID-19. Concerns of QT prolongation and increased risks of torsade's de pointes (TdP) with this combination have been raised since each agent can individually prolong the QT interval. This retrospective, observational study included hospitalized patients treated with HY and AZ from March 2020 to May 2020 at a large community hospital. Serial assessments of the QT interval were performed. Our aim is to evaluate the safety and characterize the change in QTc interval and arrhythmic events in COVID-19 patients treated with HY/AZ. A total of 21 COVID patients who received at least four days of HY and AZ were included in this study. Mean baseline was QTc 403 ms, mean maximum QTc was 440 ms, mean change in QTc was 36 ms. Only one patient (4.8%) developed prolonged QTc > 500 ms. No patient had a change in QTc of 60 ms or more. No patient developed TdP. Fifteen patients (71.4%) had hypoxia on admission, with only two patients (9.5%) required oxygen of 1-2 L at discharge. 80.9% of patients have been discharged home or inpatient rehabilitation.
2019 年冠状病毒病（COVID-19）始于中国，引发了全球大流行。很少有研究表明羟氯喹（HY）±阿奇霉素（AZ）治疗 COVID-19 的益处。由于每种药物都可以单独延长 QT 间期，因此人们对该联合用药会引起 QT 延长和尖端扭转型室性心动过速（TdP）风险增加表示担忧。这项回顾性观察性研究包括 2020 年 3 月至 2020 年 5 月在一家大型社区医院接受 HY 和 AZ 治疗的住院患者。对 QT 间期进行了连续评估。我们的目的是评估 COVID-19 患者接受 HY/AZ 治疗的安全性，并描述 QTc 间期和心律失常事件的变化特征。共有 21 名接受至少 4 天 HY 和 AZ 治疗的 COVID 患者纳入本研究。平均基线 QTc 为 403ms，平均最大 QTc 为 440ms，平均 QTc 变化为 36ms。只有 1 名患者（4.8%）出现 QTc 延长>500ms。没有患者 QTc 变化超过 60ms。没有患者发生 TdP。入院时 15 名患者（71.4%）存在缺氧，只有 2 名患者（9.5%）出院时需要 1-2L 的氧气。80.9%的患者已出院回家或接受住院康复治疗。
